2022
DOI: 10.3389/fphar.2022.877118
| |Summarize |Cite|
|
Sign up to set email alerts

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Abstract: Background: The novel and highly effective CFTR modulator combination of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del mutation. However, the impact of these modulators on gastrointestinal (GI) symptoms is relatively unknown. Therefore, the CFAbd-Score was developed and validated following FDA recommendations for development of a PROM including focus groups, multidisciplinary CF specialists, people with CF… Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
65
24
12
4

Citation Types

8
93
5
1

Year Published

Range
2022
2022
2026
2026

Publication Types

Select...
68
12
6
2

Relationship

10
78

Authors

Journals

Cited by 88 publications

(107 citation statements)

References 40 publications

8
93
5
1
Order By: Relevance
How the paper below cites the one you are viewing
“…Our data did not show important variations in BMI in children after 24 weeks of treatment with ETI. This result contrast with other studies conducted both in children >12 years and adults, 31,33 showing that ETI promotes weight gain and BMI increase. It also contrasts with an open‐label study involving 66 children aged 6–11 years, which reported a mean increase in BMI SDS of 0.37 after 24 weeks of ETI treatment 19 .…”
Section: Discussion
contrasting
confidence: 99%